147 related articles for article (PubMed ID: 2563233)
21. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
Jeste DV; Wyatt RJ
J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
[TBL] [Abstract][Full Text] [Related]
22. Neuroleptic malignant syndrome after neuroleptic discontinuation.
Amore M; Zazzeri N
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1323-34. PubMed ID: 8868212
[TBL] [Abstract][Full Text] [Related]
23. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal.
Zander KJ; Fischer B; Zimmer R; Ackenheil M
Psychopharmacology (Berl); 1981; 73(1):43-7. PubMed ID: 6112769
[TBL] [Abstract][Full Text] [Related]
24. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
25. Skin conductance responding in schizophrenic patients with abnormal involuntary movements.
Mintz M; Alfisi S; Sigal M
Psychiatry Res; 1990 Oct; 34(1):19-27. PubMed ID: 1980017
[TBL] [Abstract][Full Text] [Related]
26. The effect of chronic neuroleptic administration on cerebral dopamine receptor function.
Rupniak MN; Jenner P; Marsden CD
Life Sci; 1983 May; 32(20):2289-311. PubMed ID: 6133203
[TBL] [Abstract][Full Text] [Related]
27. Sleep patterns in cats during chronic low-dose barbiturate treatment and withdrawal.
Hinman DJ; Okamoto M
Sleep; 1984; 7(1):69-76. PubMed ID: 6538986
[TBL] [Abstract][Full Text] [Related]
28. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics.
Csernansky JG; Prosser E; Kaplan J; Mahler E; Berger PA; Hollister LE
Biol Psychiatry; 1986 Jun; 21(7):632-42. PubMed ID: 2871874
[TBL] [Abstract][Full Text] [Related]
29. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
30. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
31. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment.
Perényi A; Frecska E; Bagdy G; Révai K
Acta Psychiatr Scand; 1985 Nov; 72(5):430-5. PubMed ID: 2868608
[TBL] [Abstract][Full Text] [Related]
32. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
Waddington JL; Cross AJ; Gamble SJ; Bourne RC
Science; 1983 Apr; 220(4596):530-2. PubMed ID: 6132447
[TBL] [Abstract][Full Text] [Related]
33. The concept of supersensitivity psychosis.
Kirkpatrick B; Alphs L; Buchanan RW
J Nerv Ment Dis; 1992 Apr; 180(4):265-70. PubMed ID: 1348269
[TBL] [Abstract][Full Text] [Related]
34. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
[TBL] [Abstract][Full Text] [Related]
35. Approaches to the problem of preventing hazards of long-term neuroleptic treatment and of avoiding unnecessary drugs.
Kristjansen P
Adv Biochem Psychopharmacol; 1980; 24():505-11. PubMed ID: 6105796
[No Abstract] [Full Text] [Related]
36. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
[TBL] [Abstract][Full Text] [Related]
37. Long term treatment of tardive dyskinesia.
Jus A; Jus K; Fontaine P
J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
[TBL] [Abstract][Full Text] [Related]
38. The D1 dopamine receptor antagonist SCH 23390 enhances REM sleep in the rat.
Trampus M; Ongini E
Neuropharmacology; 1990 Oct; 29(10):889-93. PubMed ID: 2147740
[TBL] [Abstract][Full Text] [Related]
39. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension.
Maixner S; Tandon R; Eiser A; Taylor S; DeQuardo JR; Shipley J
Am J Psychiatry; 1998 Nov; 155(11):1600-2. PubMed ID: 9812125
[TBL] [Abstract][Full Text] [Related]
40. [Neuroleptics and nicotine].
Erdmann R
Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
